Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vimentin-positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics.
Ichinose Y, Hasebe T, Hirasaki M, Sakakibara A, Yokogawa H, Nukui A, Hiratsuka M, Fujimoto A, Iso C, Wakui N, Shibasaki S, Kamada K, Suzuki N, Kamakura Y, Yasuda M, Aya A, Shimada H, Matsuura K, Ishiguro H, Osaki A, Saeki T. Ichinose Y, et al. Among authors: hasebe t. Pathol Int. 2023 Sep;73(9):413-433. doi: 10.1111/pin.13350. Epub 2023 Jun 28. Pathol Int. 2023. PMID: 37378453
Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.
Hiratsuka M, Hasebe T, Ichinose Y, Sakakibara A, Fujimoto A, Wakui N, Shibasaki S, Hirasaki M, Yasuda M, Nukui A, Shimada H, Yokogawa H, Matsuura K, Hojo T, Osaki A, Saeki T. Hiratsuka M, et al. Among authors: hasebe t. Virchows Arch. 2022 Aug;481(2):161-190. doi: 10.1007/s00428-022-03337-0. Epub 2022 Jun 13. Virchows Arch. 2022. PMID: 35695928 Free PMC article.
Correction to: Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.
Hiratsuka M, Hasebe T, Ichinose Y, Sakakibara A, Fujimoto A, Wakui N, Shibasaki S, Hirasaki M, Yasuda M, Nukui A, Shimada H, Yokogawa H, Matsuura K, Hojo T, Osaki A, Saeki T. Hiratsuka M, et al. Among authors: hasebe t. Virchows Arch. 2024 May;484(5):873. doi: 10.1007/s00428-022-03486-2. Virchows Arch. 2024. PMID: 36580139 Free PMC article. No abstract available.
Granuloma after breast conserving surgery-a report of three cases.
Ichinose Y, Kosaka Y, Saeki T, Fujimoto A, Nukui A, Asano A, Shimada H, Matsuura K, Hasebe T, Osaki A. Ichinose Y, et al. Among authors: hasebe t. J Surg Case Rep. 2021 Jun 4;2021(6):rjab199. doi: 10.1093/jscr/rjab199. eCollection 2021 Jun. J Surg Case Rep. 2021. PMID: 34104403 Free PMC article.
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.
Sugitani I, Ueda S, Sakurai T, Shigekawa T, Hirokawa E, Shimada H, Takeuchi H, Matsuura K, Misumi M, Fujiuchi N, Takahashi T, Hasebe T, Osaki A, Saeki T. Sugitani I, et al. Among authors: hasebe t. Int J Clin Oncol. 2017 Oct;22(5):880-886. doi: 10.1007/s10147-017-1136-8. Epub 2017 May 25. Int J Clin Oncol. 2017. PMID: 28547525 Free PMC article. Clinical Trial.
387 results